Peptide Nucleic Acid as Therapeutic Agent

With a repeating N-(2-aminoethyl)-glycine peptide backbone coupled to purine and pyrimidine nucleobases via a linker, PNA are synthetic analogues of DNA. PNA-based technology has received a lot of interest as a viable method for gene modification due to the unique qualities of PNA, including resistance to enzymatic digestion, increased bio stability, and excellent hybridization affinity toward DNA and RNA. However, inadequate intracellular absorption presents a significant obstacle to the use of PNA. To improve PNA delivery and ensure that it reaches the appropriate spot, some solutions have been devised

    Related Conference of Peptide Nucleic Acid as Therapeutic Agent

    March 07-08, 2024

    14th World Glycobiology Congress

    Toronto, Canada
    March 28-29, 2024

    6th International Conference on Biochemistry

    Dubai, UAE
    May 16-17, 2024

    30th Asia Pacific Biotechnology Congress

    Rome, Italy
    September 25-26, 2024

    20th World Congress on Structural Biology

    Paris, France

    Peptide Nucleic Acid as Therapeutic Agent Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in